Patient leaflet - Yesintek 45 mg solution for injection in Pre-filled syringe
1. What Yesintek is and what it is used for
Yesintek contains the active substance ‘ustekinumab’, a monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind specifically to certain proteins in the body.
Yesintek belongs to a group of medicines called ‘immunosuppressants’. These medicines work by weakening part of the immune system.
What Yesintek is used for
Yesintek is used to treat the following inflammatory diseases:
- Plaque psoriasis - in adults and children aged 6 years and older
- Psoriatic arthritis - in adults
Moderate to severe Crohn’s disease - in adults and children who weigh at
least 40 kg
- Moderate to severe ulcerative colitis – in adults
Plaque psoriasis
Plaque psoriasis is a skin condition that causes inflammation affecting the skin and nails. Yesintek will reduce the inflammation and other signs of the disease.
Yesintek is used in adults with moderate to severe plaque psoriasis, who cannot use ciclosporin, methotrexate or phototherapy, or where these treatments did not work.
Yesintek is used in children and adolescents aged 6 years and older with moderate to severe plaque psoriasis who are unable to tolerate phototherapy or other systemic therapies or where these treatments did not work.
Psoriatic arthritis
Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. If you have active psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you may be given Yesintek to:
- Reduce the signs and symptoms of your disease.
- Improve your physical function.
- Slow down the damage to your joints.
Crohn’s disease
Crohn’s disease is an inflammatory disease of the bowel. If you have Crohn’s disease you will first be given other medicines. If you do not respond well enough or are intolerant to these medicines, you may be given Yesintek to reduce the signs and symptoms of your disease.
Ulcerative colitis
Ulcerative colitis is an inflammatory disease of the bowel. If you have ulcerative colitis you will first be given other medicines. If you do not respond well enough or are intolerant to these medicines, you may be given Yesintek to reduce the signs and symptoms of your disease.
Product Name Component
YESINTEK 45 mg PFS LEAFLET
390(W) x 659(H) mm;
Folded Size : 40(W) x 98(H) mm
BFXXXXXX/XX
Country
UK
Helvetica Neue LT Pro
Specification:
40 GSM ITC Paper Booklet
to be sealed with self adhesive tape.
07-08-2025-V1 | 08-08-2025-V2 | 11-08-2025-V3 | 14.08.25-V4 | 20-08-2025 \ V5 | 29-08-2025 \ V5 | 27-04-2026 \ V6
FRONT
2. What you need to know before you use Yesintek
Do not use Yesintek
If you are allergic to ustekinumab or any of the other ingredients of this
medicine (listed in section 6).
- If you have an active infection which your doctor thinks is important.
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Yesintek.
Warnings and precautions
Talk to your doctor or pharmacist before using Yesintek. Your doctor will check how well you are before each treatment. Make sure you tell your doctor about any illness you have before each treatment. Also tell your doctor if you have recently been near anyone who might have tuberculosis. Your doctor will examine you and do a test for tuberculosis, before you have Yesintek. If your doctor thinks you are at risk of tuberculosis, you may be given medicines to treat it.
Look out for serious side effects
Yesintek can cause serious side effects, including allergic reactions and infections. You must look out for certain signs of illness while you are taking Yesintek. See ‘Serious side effects’ in section 4 for a full list of these side effects.
Before you use Yesintek tell your doctor:
If you ever had an allergic reaction to Yesintek. Ask your doctor if you are
not sure.
If you have ever had any type of cancer – this is because
immunosuppressants like Yesintek weaken part of the immune system. This may increase the risk of cancer.
If you have been treated for psoriasis with other biologic medicines (a
medicine produced from a biological source and usually given by injection) – the risk of cancer may be higher.
- If you have or have had a recent infection.
If you have any new or changing lesions within psoriasis areas or on normal
skin.
If you are having any other treatment for psoriasis and/or psoriatic
arthritis – such as another immunosuppressant or phototherapy (when your body is treated with a type of ultraviolet (UV) light). These treatments may also weaken part of the immune system. Using these therapies together with Yesintek has not been studied. However, it is possible it may increase the chance of diseases related to a weaker immune system.
If you are having or have ever had injections to treat allergies – it is not
known if Yesintek may affect these.
- If you are 65 years of age or over – you may be more likely to get infections.
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Yesintek.
Some patients have experienced lupus-like reactions including skin lupus or lupus-like syndrome during treatment with ustekinumab. Talk to your doctor right away if you experience a red, raised, scaly rash sometimes with a darker border, in areas of the skin that are exposed to the sun or with joint pains.
Heart attack and strokes
Heart attack and strokes have been observed in a study in patients with psoriasis treated with Yesintek. Your doctor will regularly check your risk factors for heart disease and stroke in order to ensure that they are appropriately treated. Seek medical attention right away if you develop chest pain, weakness or abnormal sensation on one side of your body, facial droop, or speech or visual abnormalities.
Children and adolescents
Yesintek is not recommended for use in children with psoriasis under 6 years of age, children with Crohn's disease who weigh less than 40 kg or for use in children under 18 years of age with psoriatic arthritis, or ulcerative colitis because it has not been studied in this age group.
Other medicines, vaccines and Yesintek
Tell your doctor or pharmacist:
- If you are taking, have recently taken or might take any other medicines.
If you have recently had or are going to have a vaccination. Some types of
vaccines (live vaccines) should not be given while using Yesintek.
If you received Yesintek while pregnant, tell your baby’s doctor about your
Yesintek treatment before the baby receives any vaccine, including live vaccines, such as the BCG vaccine (used to prevent tuberculosis). Live vaccines are not recommended for your baby in the first twelve months after birth if you received Yesintek during the pregnancy unless your baby’s doctor recommends otherwise.
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are planning to have a baby,
ask your doctor for advice before taking this medicine.
A higher risk of birth defects has not been seen in babies exposed to Yesintek
in the womb. However, there is limited experience with Yesintek in pregnant women. It is therefore preferable to avoid the use of Yesintek in pregnancy.
If you are a woman of childbearing potential, you are advised to avoid
becoming pregnant and must use adequate contraception while using Yesintek and for at least 15 weeks after the last Yesintek treatment.
Yesintek can pass across the placenta to the unborn baby. If you received
Yesintek during your pregnancy, your baby may have a higher risk for getting an infection.
It is important that you tell your baby’s doctors and other health care
professionals if you received Yesintek during your pregnancy before the baby receives any vaccine. Live vaccines such as the BCG vaccine (used to prevent tuberculosis) are not recommended for your baby in the first twelve months after birth if you received Yesintek during the pregnancy unless your baby’s doctor recommends otherwise.
Ustekinumab may pass into breast milk in very small amounts. Talk to your
doctor if you are breast-feeding or are planning to breast-feed. You and your doctor should decide if you should breast-feed or use Yesintek - do not do both.
Driving and using machines
Yesintek has no or negligible influence on the ability to drive and use machines.
Yesintek contains Polysorbate 80 (E433)
Yesintek contains 0.02 mg of polysorbate 80 (E433) in each 45 mg/0.5 mL PFS which is equivalent to 0.02 mg/0.5 mL (0.0003 mg/kg/day). Polysorbates may cause allergic reactions. Tell your doctor if you have or your child has any known allergies.
3. How to use Yesintek
Yesintek is intended for use under the guidance and supervision of a doctor experienced in treating conditions for which Yesintek is intended.
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Talk to your doctor about when you will have your injections and follow-up appointments.
How much Yesintek is given
Your doctor will decide how much Yesintek you need to use and for how long.
Adults aged 18 years or older
Psoriasis or Psoriatic Arthritis
The recommended starting dose is 45 mg Yesintek. Patients who weigh more
than 100 kilograms (kg) may start on a dose of 90 mg instead of 45 mg.
After the starting dose, you will have the next dose 4 weeks later, and then
every 12 weeks. The following doses are usually the same as the starting dose.
Crohn’s disease or Ulcerative Colitis
During treatment, the first dose of approximately 6 mg/kg Yesintek will be
given by your doctor through a drip in a vein in your arm (intravenous infusion). After the starting dose, you will receive the next dose of 90 mg Yesintek after 8 weeks, then every 12 weeks thereafter by an injection under the skin (‘subcutaneously’).
In some patients, after the first injection under the skin, 90 mg Yesintek may
be given every 8 weeks. Your doctor will decide when you should receive your next dose.
Children and adolescents aged 6 years or older
Psoriasis
The doctor will work out the right dose for you, including the amount (volume)
of Yesintek to be injected to give the right dose. The right dose for you will depend on your body weight at the time each dose is given.
A 45 mg vial is available for children who need to receive less than the full
45 mg dose.
If you weigh less than 60 kg, the recommended dose is 0.75 mg of Yesintek
per kg body weight.
- If you weigh 60 kg to 100 kg, the recommended dose is 45 mg Yesintek.
- If you weigh more than 100 kg, the recommended dose is 90 mg Yesintek.
After the starting dose, you will have the next dose 4 weeks later, and then
every 12 weeks.
Children who weigh at least 40 kg Crohn’s disease
During treatment, the first dose of approximately 6 mg/kg Yesintek will be given
by your doctor through a drip in a vein in your arm (intravenous infusion). After the starting dose, you will receive the next dose of 90 mg Yesintek after 8 weeks, then every 12 weeks thereafter by an injection under the skin (‘subcutaneously’).
In some patients, after the first injection under the skin, 90 mg Yesintek may be
given every 8 weeks. Your doctor will decide when you should receive your next dose.
How Yesintek is given
Yesintek is given as an injection under the skin (‘subcutaneously’). At the start
of your treatment, medical or nursing staff may inject Yesintek.
However, you and your doctor may decide that you may inject Yesintek
yourself. In this case you will get training on how to inject Yesintek yourself.
For instructions on how to inject Yesintek, see ‘Instructions for administration’
at the end of this leaflet.
Talk to your doctor if you have any questions about giving yourself an injection.
If you use more Yesintek than you should
If you have used or been given too much Yesintek, talk to a doctor or pharmacist straight away. Always have the outer carton of the medicine with you, even if it is empty.
If you forget to use Yesintek
If you forget a dose, contact your doctor or pharmacist. Do not take a double dose to make up for a forgotten dose.
If you stop using Yesintek
It is not dangerous to stop using Yesintek. However, if you stop, your symptoms may come back.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Some patients may have serious side effects that may need urgent treatment.
Allergic reactions – these may need urgent treatment. Tell your doctor or get emergency medical help straight away if you notice any of the following signs.
Serious allergic reactions (‘anaphylaxis’) are rare in people taking Yesintek
(may affect up to 1 in 1 000 people). Signs include:
o difficulty breathing or swallowing
o low blood pressure, which can cause dizziness or light-headedness
o swelling of the face, lips, mouth or throat.
- Common signs of an allergic reaction include skin rash and hives (these may affect up to 1 in 100 people).
In rare cases, allergic lung reactions and lung inflammation have been reported in patients who receive ustekinumab. Tell your doctor right away if you develop symptoms such as cough, shortness of breath, and fever.
If you have a serious allergic reaction, your doctor may decide that you should not use Yesintek again.
Infections – these may need urgent treatment. Tell your doctor straight away if you notice any of the following signs.
- Infections of the nose or throat and common cold are common (may affect up to 1 in 10 people)
- Infections of the chest are uncommon (may affect up to 1 in 100 people)
- Inflammation of tissue under the skin (‘cellulitis’) is uncommon (may affect up to 1 in 100 people)
Shingles (a type of painful rash with blisters) are uncommon (may affect up to
1 in 100 people)
Yesintek may make you less able to fight infections. Some infections could become serious and may include infections caused by viruses, fungi, bacteria (including tuberculosis), or parasites, including infections that mainly occur in people with a weakened immune system (opportunistic infections).
Opportunistic infections of the brain (encephalitis, meningitis), lungs, and eye have been reported in patients receiving treatment with ustekinumab.
You must look out for signs of infection while you are using Yesintek. These include:
- fever, flu-like symptoms, night sweats, weight loss
- feeling tired or short of breath; cough which will not go away
- warm, red and painful skin, or a painful skin rash with blisters
- burning when passing water
- diarrhoea
- visual disturbance or vision loss
- headache, neck stiffness, light sensitivity, nausea or confusion.
Tell your doctor straight away if you notice any of these signs of infection. These may be signs of infections such as chest infections, skin infections, shingles or opportunistic infections that could have serious complications. Tell your doctor if you have any kind of infection that will not go away or keeps coming back. Your doctor may decide that you should not use Yesintek until the infection goes away. Also tell your doctor if you have any open cuts or sores as they might get infected.
Shedding of skin – increase in redness and shedding of skin over a larger area of the body may be symptoms of erythrodermic psoriasis or exfoliative dermatitis, which are serious skin conditions. You should tell your doctor straight away if you notice any of these signs.
Other side effects
Common side effects (may affect up to 1 in 10 people):
- Diarrhoea
- Nausea
- Vomiting
- Feeling tired
- Feeling dizzy
- Headache
- Itching (‘pruritus’)
- Back, muscle or joint pain
- Sore throat
- Redness and pain where the injection is given
- Sinus infection
Uncommon side effects (may affect up to 1 in 100 people):
- Tooth infections
- Vaginal yeast infection
- Depression
- Blocked or stuffy nose
- Bleeding, bruising, hardness, swelling and itching where the injection is given
- Feeling weak
Drooping eyelid and sagging muscles on one side of the face (‘facial palsy’ or
‘Bell’s palsy’), which is usually temporary
- A change in psoriasis with redness and new tiny, yellow or white skin blisters, sometimes accompanied by fever (pustular psoriasis)
- Peeling of the skin (skin exfoliation)
- Acne
Rare side effects (may affect up to 1 in 1 000 people):
- Redness and shedding of skin over a larger area of the body, which may be itchy or painful (exfoliative dermatitis). Similar symptoms sometimes develop as a natural change in the type of psoriasis symptoms (erythrodermic psoriasis)
- Inflammation of small blood vessels, which can lead to a skin rash with small red or purple bumps, fever or joint pain (vasculitis)
Very rare side effects (may affect up to 1 in 10 000 people):
- Blistering of the skin that may be red, itchy, and painful (Bullous pemphigoid)
- Skin lupus or lupus-like syndrome (red, raised scaly rash on areas of the skin exposed to the sun possibly with joint pains)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Yesintek
- Keep this medicine out of the sight and reach of children.
- Store in a refrigerator (2 °C–8 °C). Do not freeze.
- Keep the pre-filled syringe in the outer carton in order to protect from light.
- If needed, individual Yesintek pre-filled syringes may also be stored at room temperature up to 30°C for a maximum single period of up to 30 days in the original carton in order to protect from light. Record the date when the pre-filled syringe is first removed from the refrigerator and the discard date in the space provided on the outer carton. The discard date must not exceed the original expiry date printed on the carton. Once a syringe has been stored at room temperature (up to 30 °C), it should not be returned to the refrigerator. Discard the syringe if not used within 30 days at room temperature storage or by the original expiry date, whichever is earlier.
- Do not shake Yesintek pre-filled syringes. Prolonged vigorous shaking may damage the medicine.
Do not use this medicine:
After the expiry date which is stated on the label and the carton after ‘EXP’.
The expiry date refers to the last day of that month.
- After discard date recorded on the carton once stored at room temperature, i.e., more than 30 days at 30°C.
- If the liquid is discoloured, cloudy or you can see other foreign particles floating in it (see section 6 ‘What Yesintek looks like and contents of the pack’).
If you know, or think that it may have been exposed to extreme temperatures
(such as accidentally frozen or heated).
- If the product has been shaken vigorously.
Yesintek is for single use only. Any unused product remaining in the syringe should be thrown away. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Yesintek contains
- The active substance is ustekinumab. Each pre-filled syringe contains 45 mg ustekinumab in 0.5 mL.
- The other ingredients are L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80 (E433), sucrose, sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment) and water for injections.
What Yesintek looks like and contents of the pack
Yesintek is a clear, colorless to pale yellow solution for injection. It is supplied as a carton pack containing 1 single-dose, glass 1 mL pre-filled syringe. Each pre-filled syringe contains 45 mg ustekinumab in 0.5 mL of solution for injection.
Marketing Authorisation Holder
Biosimilar Collaborations Ireland Limited
Unit 35/36 Grange Parade, Baldoyle Industrial Estate
Dublin 13, DUBLIN Ireland, D13 R20R
Manufacturers
Biosimilar Collaborations Ireland Limited
Block B, The Crescent Building, Santry Demesne, Dublin
D09 C6X8, Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
United Kingdom
Biosimilars Newco Limited
Tel: 0080008250910
This leaflet was last revised in April 2026
BACK
Gather the supplies 5. After the injection:
TM
Yesintek
BFXXXXXX/XX
BFXXXXXX/XX
Yesintek
TM
Figure 7 Instructions for administration
Get everything together that you need and lay out on a well-lit, clean and flat surface. This includes
Figure 1 shows what the pre-filled syringe looks like
You may notice an air bubble in the pre-filled syringe or a drop
- Press an antiseptic wipe over the injection site for a few seconds after the injection.
of liquid at the end of the needle. These are both normal and do not need to be removed
- antiseptic wipes,
Before Usage After Usage
- There may be a small amount of blood or liquid at the injection
Used Plunger head
- a cotton ball or gauze,
Plunger head
site. This is normal.
- Do not touch the needle or allow it to touch any surface
- and a sharps container
Plunger
- You can press a cotton ball or gauze over the injection site and
- Do not use the pre-filled syringe if it is dropped without the
Used Syringe Barrel
- your prescribed dose of Yesintek injection (See Figure 2)

Figure 2
Storage information Instructions for administration of Yesintek injection.
hold for 10 seconds.
Needle guard wings
needle cover in place. If this happens, please contact your doctor or pharmacist
- Do not rub the skin at the injection site. You may cover the
Finger grips
injection site with a small adhesive bandage, if necessary.
Viewing window
- lnject the dose promptly after removing the needle cover.
Body
Label and Expiration date
Used Needle
Syringe Barrel (Body)
Needle Safety Guard
Used Needle
Safety Spring
Needle safety spring
Needle Cover
Needle cover
ADHESIVE
ANTISEPTIC
COTTON BALLS OR GAUZE PADS
SHARPS DISPOSAL
YESINTEK PREFILLED
- 4. lnject the dose 6. Disposal:
BANDAGE
WIPES
CONTAINER
SYRINGE
- Used syringes should be placed in a puncture-resistant container,
Hold the pre-filled syringe with one hand between the middle
like a sharps container (see Figure 10). Never re-use a syringe, for your safety and health and for the safety of others. Dispose of your sharps container according to your local regulations.
and index fingers and place the thumb on top of the plunger head and use the other hand to gently pinch the cleaned skin between your thumb and index finger.
- Choose and prepare the injection site:
At the start of treatment, your healthcare provider will assist you with your first injection. However, you and your doctor may decide that you may inject Yesintek yourself. If this happens, you will get training on how to inject Yesintek.
Revised: April/ 2026 Choose an injection site( see Figure 3)
- Antiseptic wipes and other supplies can be disposed of in your
- Do not squeeze it tightly
Yesintek is given by injection under the skin (subcutaneously).
garbage.
- Do not pull back on the plunger at anytime
Good places for the injection are the upper thigh or around the
belly (abdomen) at least 5 cm away from the navel (belly button).
- In a single and swift motion, insert the needle through the skin
Talk to your doctor if you have any questions about giving yourself an injection.
If possible, do not use areas of skin that show signs of psoriasis.
as far as it will go (see Figure 6)
- If someone will assist in giving you the injection, then he or she
Do not mix Yesintek with other liquids for injection.
may also choose the upper arms as an injection site
Do not shake Yesintek pre-filled syringes. This is because strong
shaking may damage the medicine. Do not use the medicine if it has been shaken strongly.
1.Check the number of pre-filled syringes and prepare the materials:
Preparing for use of the pre-filled syringe
Take the pre-filled syringe(s) out of the refrigerator. Let the
Figure 6
pre-filled syringe stand outside the box for about half an hour. This will let the liquid come to a comfortable temperature for injection (room temperature). Do not remove the syringe's needle cover while allowing it to reach room temperature
Figure 3
Inject all of the medication by pushing in the plunger until the plunger head is completely between the needle guard wings (see Figure 7)
*Areas in blue are recommended injection sites.
Prepare the injection site
Hold the pre-filled syringe by the body of the syringe with the
- Choose a well-lit, clean, flat work surface.
covered needle pointing upward
Figure 9 Needle guard wings
- Wash your hands very well with soap and warm water
- Do not hold by the plunger head, plunger, needle guard wings, or
- Wipe the injection site on the skin with an antiseptic wipe
needle cover
- Do not touch this area again before giving the injection. Let your
Do not pull back on the plunger at anytime
skin dry before injecting.
- Do not attempt to remove the needle safety guard from the
- Remove prefilled syringe tray from carton
pre-filled syringe
Do not remove the needle cover from the pre-filled syringe until
- Open the tray by peeling away the cover. Hold the Needle safety
instructed to do so
guard (as shown in the Figure 4) to remove the prefilled syringe from the tray
Check the pre-filled syringe(s) to make sure the number of
pre-filled syringes and strength is correct If your dose is 45 mg you will get one 45 mg pre-filled syringe of Yesintek If your dose is 90 mg you will get two 45 mg pre-filled syringes of Yesintek and you will need to give yourself two injections. Choose two different sites for these injections (e.g. one injection in the right thigh and the other injection in the left thigh) and give the injections one right after the other.
Manufactured by: Biosimilar Collaborations Ireland Limited
When the plunger is pushed as far as it will go, continue to keep the pressure on the plunger head, take out the needle and let go of the skin (see Figure 8)
Block B, The Crescent Building, Santry Demesne Dublin
D09 C6X8
Ireland
Marketed by: Biosimilar Collaborations Ireland Limited
- it is the right medicine
it has not passed its expiry date
Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13, DUBLIN Ireland, D13
Grasp Here
the pre-filled syringe is not damaged
Figure 4
the solution in the pre-filled syringe is clear, colourless to pale
R20R
- Hold the prefilled syringe with the covered needle pointing
yellow
upward.
the solution on the pre-filled syringe is not discoloured or cloudy
and does not contain any foreign particles.
the solution in the pre-filled syringe is not frozen.
- 3. Remove the needle cover (see Figure 5):
Get everything together that you need and lay out on a well-lit
clean and flat surface. This includes antiseptic wipes, cotton ball or gauze, and a sharps container
Slowly take your thumb off the plunger head to allow the empty syringe to move up until the entire needle is covered by the needle guard, as shown by Figure 9:
The needle cover should not be removed until you are ready to
inject the dose
Pick up the pre-filled syringe, hold the body of the syringe with
one hand
- Pull the needle cover straight off and throw it away. Do not touch
Yesintek prefilled syringes must be refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light until the time of use.
the plunger while you do this
- Do not freeze. Do not shake.
If needed, individual prefilled syringes may be stored at room
temperature up to 30 °C (86 °F) for a maximum single period of up to 30 days in the original carton to protect from light.
Once a syringe has been stored at room temperature, it should
not be returned to the refrigerator.
Discard the syringe if not used within 30 days at room
temperature storage
Figure 5
Yesintek, PFS IFU
Product Name Component
390(W) x 600(H) mm ;
BFXXXXXX/XX
Folded Size : 100(W) x 40(H) mm
Country
UK
11258
Helvetica Neue LT Pro
Specification:
Paper: 60gsm Maplitho Paper Booklet to be sealed with self adhesive tape
